Skip to main content
Home

Main navigation

  • Home
  • News
  • Target proteins
    • ACE2 Receptor
      • Spike Binding Interface - Site 1
      • Spike Binding Interface - Site 2
      • Dynamic Pocket 1
      • Dynamic Pocket 2
    • TMPRSS2
      • Active Site
    • Spike Protein (S)
      • ACE2 Binding Site
      • HR1 Domain - HR2 Binding Interface
    • ORF7a
      • Surface (Blind Docking)
    • Macrodomain (nsp3)
      • Active Site
    • PLpro (nsp3)
      • Active Site
      • Accessory Pocket
      • DUB Binding Site
    • Mpro (nsp5)
      • Active Site
      • Dimerization Site
      • Alpha Helix 5 Association Site
    • nsp7
      • Surface (Blind Docking)
    • nsp8
      • nsp12 Binding Interface
      • nsp7 Binding Site
    • nsp9
      • Homodimerization Site 1
      • Homodimerization Site 2
    • nsp10
      • Site 1 - nsp14/16 Binding Site
      • Site 2 - nsp14 Binding Site
    • RdRP (nsp12)
      • RNA Binding Site 1
      • RNA Binding Site 2
      • Nucleotide Binding Site
      • nsp8 binding Interface
      • nsp7 Binding Interface
    • Helicase (nsp13)
      • Active Site
      • RNA Binding Site 1
      • RNA Binding Site 2
    • N7-MTase, ExoN (nsp14)
      • nsp10 Binding Interface
      • Active Site (ExoN)
      • Active Site (N7-MTase)
    • XendoU (nsp15)
      • Active Site
    • 2'-O-MTase (nsp16)
      • nsp16 Binding Interface
      • Active Site
    • Nucleoprotein (N)
      • NTD RNA Binding Interface
      • NTD Oligomerization Interface
      • CTD Dimerization Interface
      • CTD Oligomerization Interface
  • Special Datasets
    • World-Approved Drugs
    • Investigational Drugs
    • In-Man Compounds
    • Natural Products
  • Community
  • About
    • FAQ
    • Team
  • 🔍

XendoU (nsp15)

Copyright © The President and Fellows of Harvard College

User account menu

  • Log in